Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

ANKRD43 Inhibitors

ANKRD43 inhibitors encompass a class of chemicals tha interact with the Ankyrin repeat domain-containing protein SOWAHA, a protein encoded by the ANKRD43 gene. These inhibitors do not target the protein directly, given the current lack of specific antagonists, but rather modulate the activity of ANKRD43 by influencing signaling pathways and cellular processes with which it is associated. Proteins with ankyrin repeats are known to participate in various cellular mechanisms, including signal transduction, cell cycle control, and the maintenance of cellular architecture. Therefore, the inhibitors in this class likely act on those cellular processes that indirectly affect the function of ANKRD43. The chemical compounds that fall under this category are diverse and could target various stages of the signaling pathways, from the initiation of the signal at the cell surface to the final execution of biological responses in the nucleus or cytoplasm.

In terms of specific actions, such inhibitors may prevent protein-protein interactions that are crucial for the signaling cascades involving ANKRD43, or they may alter the post-translational modification of proteins that interact with ANKRD43, thereby changing its activity. For example, kinase inhibitors in this class could prevent the phosphorylation of proteins that are part of the signaling complexes with ANKRD43, thus modifying the protein's role in the signal transduction pathway. Similarly, proteasome inhibitors might increase the stability of proteins that are otherwise marked for degradation, which could enhance or reduce the functional interactions of ANKRD43 within the cell. The variety of chemicals that could be classified as ANKRD43 inhibitors is broad, reflecting the multitude of possible indirect mechanisms of action. These could include small molecule inhibitors, organic compounds, or other synthetic chemicals that are known to affect signaling pathways like NF-κB, Wnt, Notch, MAPK, PI3K, or mTOR, all of which are known to engage ankyrin repeat-containing proteins in some context. Each inhibitor would have a specific molecular target within these pathways, yet the outcome would converge on the modulation of ANKRD43 function, influencing the biological processes in which this protein is a participant. The effectiveness of these inhibitors is dependent on the precise nature of ANKRD43's involvement in cellular signaling and would be an area for detailed investigation to elucidate the protein's role in cellular physiology.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

BAY 11-7082

19542-67-7sc-200615B
sc-200615
sc-200615A
5 mg
10 mg
50 mg
$62.00
$85.00
$356.00
155
(1)

BAY 11-7082 can interfere with NF-κB pathway signaling by preventing IκBα phosphorylation, which may reduce the interaction between NF-κB-regulated transcription factors and ANKRD43 if it is part of this signaling complex.

IWR-1-endo

1127442-82-3sc-295215
sc-295215A
5 mg
10 mg
$82.00
$135.00
19
(1)

IWR-1-endo can inhibit the Wnt signaling pathway by stabilizing Axin; this action may alter the association of ANKRD43 with proteins in the Wnt pathway, assuming ANKRD43 is involved in such protein complexes.

DAPT

208255-80-5sc-201315
sc-201315A
sc-201315B
sc-201315C
5 mg
25 mg
100 mg
1 g
$40.00
$120.00
$480.00
$2141.00
47
(3)

DAPT can block the proteolytic cleavage of Notch receptors by inhibiting γ-secretase, potentially impacting ANKRD43's function if it interacts with the Notch signaling components.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

PD 98059 can block the MAPK/ERK pathway by inhibiting MEK, which might change the phosphorylation state of proteins that interact with ANKRD43, affecting its function.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

SB 203580 can inhibit p38 MAPK, which may affect ANKRD43's function if it is part of a protein complex that is regulated by the p38 MAPK signaling pathway.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY 294002 can inhibit PI3K, potentially disrupting downstream signaling that modulates protein interactions involving ANKRD43 within those pathways.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125 can inhibit JNK, potentially modifying the interaction of ANKRD43 with proteins that are regulated by the JNK signaling pathway.

MG-132 [Z-Leu- Leu-Leu-CHO]

133407-82-6sc-201270
sc-201270A
sc-201270B
5 mg
25 mg
100 mg
$60.00
$265.00
$1000.00
163
(3)

MG-132 [Z-Leu- Leu-Leu-CHO] can prevent the degradation of proteins by the proteasome, potentially increasing the stability of proteins that interact with ANKRD43, thus affecting its functional role in the cell.

Cyclopamine

4449-51-8sc-200929
sc-200929A
1 mg
5 mg
$94.00
$208.00
19
(1)

Cyclopamine can inhibit Hedgehog signaling by targeting Smoothened; if ANKRD43 is associated with this pathway, its function might be affected by alterations in pathway activity.

XAV939

284028-89-3sc-296704
sc-296704A
sc-296704B
1 mg
5 mg
50 mg
$36.00
$117.00
$525.00
26
(1)

XAV939 can promote the degradation of β-catenin, thereby potentially disrupting interactions of ANKRD43 with components of the Wnt signaling pathway.